DR. PRATIK MULTANI, MD
Osteopathic Medicine at Belmont Trail Ct, San Diego, CA
License number
California G86239
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
6293 Belmont Trail Ct, San Diego, CA 92130
Phone
(858) 705-2846
Personal information
See more information about PRATIK MULTANI at radaris.comName
Address
Phone
10486 Harvest View Way, San Diego, CA 92128
10486 Harvest View Way, Ramona, CA 92065
11858 Stoney Peak Dr, San Diego, CA 92128
10486 Harvest View Way, San Diego, CA 92128
Organization information
See more information about PRATIK MULTANI at bizstanding.comPratik Multani MD
6293 Belmont Trl Ct, San Diego, CA 92130
Industry:
Internist
Phone:
(858) 431-8500 (Phone)
Pratik Sharad Multani
Professional information
See more information about PRATIK MULTANI at trustoria.com
Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism
Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism
US Patent:
2007000, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/417984
Inventors:
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 39/395, A61K 38/13, A61K 31/553, A61K 31/551, A61K 31/455, A61K 31/4709, A61K 31/704, A61K 31/277, A61K 31/138
US Classification:
424155100, 514220000, 514011000, 514026000, 514263320, 514317000, 514469000, 514253040, 514389000, 514291000, 514225800, 514314000, 514355000, 514211070, 514521000, 514651000
Abstract:
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.
Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism
Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism
US Patent:
2007000, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/418323
Inventors:
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glen - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glen - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 39/395, A61K 31/704, A61K 31/7048, A61K 31/4709, A61K 31/4745, A61K 31/337
US Classification:
424155100, 424178100, 514314000, 514283000, 514449000, 514034000, 514027000
Abstract:
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.
Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism
Treatment Of Cancer Patients Exhibiting Activation Of The P-Glycoprotein Efflux Pump Mechanism
US Patent:
2007000, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/418399
Inventors:
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 39/395, G01N 33/574, A61K 31/704, A61K 31/525, A61K 31/4745, A61K 31/4709
US Classification:
424155100, 435007230, 424178100, 514314000, 514251000, 514283000, 514034000, 514410000
Abstract:
The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic agent in combination with zosuquidar. The methods are particularly effective in treating acute myelogenous leukemia, metastatic breast cancer, and other cancers expressing P-glycoprotein, wherein the P-glycoprotein expression and/or function is used to select a treatment option for the patient.
Chemotherapeutic Formulations Of Zosuquidar Trihydrochloride And Modified Cyclodextrins
Chemotherapeutic Formulations Of Zosuquidar Trihydrochloride And Modified Cyclodextrins
US Patent:
2007001, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/418400
Inventors:
Jeff Schwegman - Bloomington IN, US
Mark Edgar - Rancho Santa Fe CA, US
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Mark Edgar - Rancho Santa Fe CA, US
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 31/724
US Classification:
514058000
Abstract:
The present invention relates to a method of treating patients with leukemias, solid tumors, and other malignancies using chemotherapeutic agents in combination with zosuquidar that has been solubilized by a modified cyclodextrin, such as sulfobutylcyclodextrin or hydroxypropyl cyclodextrin. The invention is also directed to pharmaceutical formulations comprising zosuquidar in combination with a modified cyclodextrin.
Treatment Of Patients With Cancer Using A Calicheamicin-Antibody Conjugate In Combination With Zosuquidar
Treatment Of Patients With Cancer Using A Calicheamicin-Antibody Conjugate In Combination With Zosuquidar
US Patent:
2007000, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/416992
Inventors:
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 39/395, A61K 31/4709
US Classification:
424155100, 424178100, 514314000
Abstract:
The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML) and metastatic breast cancer.
Hematopoietic Stem And Progenitor Cell Therapy
Hematopoietic Stem And Progenitor Cell Therapy
US Patent:
2014003, Jan 30, 2014
Filed:
Aug 12, 2011
Appl. No.:
13/816723
Inventors:
Daniel Shoemaker - San Diego CA, US
Pratik Multani - San Diego CA, US
Caroline Desponts - San Diego CA, US
David L. Robbins - Temecula CA, US
Paul Grayson - La Jolla CA, US
John Mendlein - Encinitas CA, US
Pratik Multani - San Diego CA, US
Caroline Desponts - San Diego CA, US
David L. Robbins - Temecula CA, US
Paul Grayson - La Jolla CA, US
John Mendlein - Encinitas CA, US
Assignee:
FATE THERAPEUTICS, INC. - San Diego CA
International Classification:
C12N 5/0789, A61K 35/28
US Classification:
424 937, 435375
Abstract:
The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of modified hematopoietic stem and/or progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic composition. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
Zosuquidar, Daunorubicin, And Cytarabine For The Treatment Of Cancer
Zosuquidar, Daunorubicin, And Cytarabine For The Treatment Of Cancer
US Patent:
2007001, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/416571
Inventors:
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 31/704, A61K 31/4709, A61K 31/4745, A61K 31/337
US Classification:
514034000, 514314000, 514283000, 514449000
Abstract:
The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).
Zosuquidar, Daunorubicin, And Cytarabine For The Treatment Of Cancer
Zosuquidar, Daunorubicin, And Cytarabine For The Treatment Of Cancer
US Patent:
2007001, Jan 11, 2007
Filed:
May 3, 2006
Appl. No.:
11/416832
Inventors:
Branimir Sikic - Stanford CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
Daniel Hoth - San Francisco CA, US
David Socks - Carlsbad CA, US
Scott Glenn - La Jolla CA, US
John Marcelletti - San Diego CA, US
Michael Walsh - San Diego CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 31/7072, A61K 31/704, A61K 31/4709
US Classification:
514034000, 514049000, 514314000
Abstract:
The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML).
Cancer Treatments
Cancer Treatments
US Patent:
2009020, Aug 20, 2009
Filed:
Feb 18, 2009
Appl. No.:
12/372910
Inventors:
Heather Helene Bendall - Del Mar CA, US
Gary T. Elliott - San Diego CA, US
Lorenzo M. Leoni - Lodrino, CH
Christina Carol Niemeyer - Poway CA, US
Pratik S. Multani - San Diego CA, US
Gary T. Elliott - San Diego CA, US
Lorenzo M. Leoni - Lodrino, CH
Christina Carol Niemeyer - Poway CA, US
Pratik S. Multani - San Diego CA, US
International Classification:
A61K 31/4184, A61P 35/00
US Classification:
514394
Abstract:
Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such treatments are also provided.
Cancer Treatments
Cancer Treatments
US Patent:
2006012, Jun 15, 2006
Filed:
Nov 4, 2005
Appl. No.:
11/267010
Inventors:
Heather Bendall - Del Mar CA, US
Gary Elliott - San Diego CA, US
Lorenzo Leoni - Lodrino, CH
Christina Niemeyer - Poway CA, US
Pratik Multani - San Diego CA, US
Gary Elliott - San Diego CA, US
Lorenzo Leoni - Lodrino, CH
Christina Niemeyer - Poway CA, US
Pratik Multani - San Diego CA, US
International Classification:
A61K 31/4184
US Classification:
514394000
Abstract:
Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such treatments are also provided.